Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire 7 days ago

ProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

GlobeNewswire 9 days ago

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

GlobeNewswire October 30, 2024

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

GlobeNewswire September 12, 2024

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 5, 2024

ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire August 8, 2024

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

GlobeNewswire August 6, 2024

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

GlobeNewswire August 1, 2024

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

GlobeNewswire July 30, 2024

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

GlobeNewswire July 26, 2024

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

GlobeNewswire July 26, 2024

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire May 14, 2024

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

GlobeNewswire April 30, 2024

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

GlobeNewswire April 9, 2024

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April 

GlobeNewswire April 4, 2024

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

GlobeNewswire April 1, 2024

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

GlobeNewswire March 11, 2024

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

GlobeNewswire February 22, 2024

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

GlobeNewswire January 22, 2024

ProMIS Neurosciences Issues Letter to Shareholders

GlobeNewswire January 8, 2024